The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Beth O'Quin.

## DIGEST

SB 48 Engrossed

## 2024 Regular Session

Talbot

<u>Present law</u> requires any health coverage plan renewed, delivered, or issued for delivery in this state to include coverage for biomarker testing for the purpose of the diagnosis, treatment, appropriate management, or ongoing monitoring of an individual's disease or condition when the test provides clinical utility as demonstrated by medical and scientific evidence, including any one of the following:

- (1) Labeled indications for diagnostic tests approved or cleared by the U.S. Food and Drug Administration (FDA) or indicated diagnostic tests for a drug approved by the FDA.
- (2) Warnings and precautions listed on a FDA-approved drug label.
- (3) National Coverage Determinations of the Centers for Medicare and Medicaid Services or Local Coverage Determinations of Medicare Administrative Contractors.
- (4) Nationally recognized clinical practice guidelines.

<u>Present law</u> requires implementation of <u>present law</u> when a specific appropriation is made to make <u>present law</u> effective.

<u>Proposed law</u> repeals <u>present law</u> requiring a specific appropriation be made to make <u>present law</u> effective.

<u>Proposed law</u> applies to any new policy, contract, program, or health coverage plan issued on or after Jan. 1, 2025.

Effective upon signature of the governor or lapse of time for gubernatorial action.

(Amends Section 3 of Act No. 324 of 2023 RS)

## Summary of Amendments Adopted by Senate

## Committee Amendments Proposed by Senate Committee on Insurance to the original bill

- 1. Removes the consensus statement definition.
- 2. Removes enforcement provisions.
- 3. Changes the applicability date to January 1, 2025.
- 4. Makes technical changes.